pazopanib-hcl

Description: Pazopanib HCl (formerly GW786034 HCl; GW-786034; trade name Votrient) is a novel and potent multi-targeted receptor tyrosine kinase inhibitor with potential anticancer activity. It inhibits VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 values of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. Pazopanib is an FDA approved drug for treating advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas.

References: J Med Chem. 2008 Aug 14; 51(15):4632-40; J Orthop Res. 2012 Sep; 30(9):1493-8.

Related CAS #: 444731-52-6 (free base)

Pazopanib HCl; Pazopanib Hydrochloride; GW786034 Hydrochloride; GW786034 HCl; GW-78603; GW 786034; GW786034; GW-78603HCl; GW 786034 HCl; GW 786034; Pazopanib; trade name: Votrient.;

SMILES: CC1=CC=C(C=C1S(N)(=O)=O)NC2=NC=CC(N(C3=CC4=NN(C(C)=C4C=C3)C)C)=N2.Cl